Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

[at noodls] – THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated … . . . → Read More: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financial Results Amgen Inc. (NASDAQ:AMGN) ~ Amgen announces MENDEL-2 Phase 3 trial met co-primary endpoints AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial